Back

Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

19 May 2025 (16:00 - 16:45)
Organised by: Logo
Congress Presentation Part of: Digitoxin and other therapeutic strategic advances Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices
Doctor P. Marques (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study
Professor I. Gruev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials
Doctor R. Laborante (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)
Ms J. van Eijk (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Digitoxin and other therapeutic strategic advances

The Event

Event poster

Heart Failure 2025

19 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure
thumbnail
Congress Presentation
Hematological outcomes of SGLT-2 inhibitors in heart failure patients: a systematic review and meta-analysis
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on renal function and cardiovascular outcomes in heart failure: Korean heart failure III registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources